SciTech Development

Executive Summary

SciTech Development is a specialty pharmaceutical company advancing cancer treatment through its proprietary Small Delivery Platform (SDP). The platform enables safer and more effective drug delivery, with the lead candidate ST-001 nanoFenretinide combining SDP with fenretinide, a promising anticancer agent. ST-001 is designed to improve bioavailability and reduce toxicity compared to conventional fenretinide. The company is currently in Phase 1 clinical development, having completed preclinical studies demonstrating enhanced efficacy and safety. With a focus on addressing unmet needs in oncology, SciTech's platform has potential for broader application across multiple therapeutic areas. The company is privately held, headquartered in Grosse Pointe Farms, Michigan, and has been operating since 2003.

Upcoming Catalysts (preview)

• Q4 2026Phase 1 interim data readout for ST-001 nanoFenretinide60% success
• H1 2027Strategic partnership or licensing agreement for SDP platform40% success
• Q3 2026FDA IND amendment or orphan drug designation for ST-00170% success